Metokuriinijodidi
Metokuriinijodidi Brand names, Metokuriinijodidi Analogs
Metokuriinijodidi Brand Names Mixture
- No information avaliable
Metokuriinijodidi Chemical_Formula
C23H31NO7
Metokuriinijodidi RX_link
http://www.rxlist.com/cgi/generic3/cellcept.htm
Metokuriinijodidi fda sheet
Metokuriinijodidi msds (material safety sheet)
Metokuriinijodidi Synthesis Reference
No information avaliable
Metokuriinijodidi Molecular Weight
469.955 g/mol
Metokuriinijodidi Melting Point
No information avaliable
Metokuriinijodidi H2O Solubility
Slightly soluble (43 mg/mL at pH 7.4)
Metokuriinijodidi State
Solid
Metokuriinijodidi LogP
2.424
Metokuriinijodidi Dosage Forms
Capsule (250mg); Tablet (500 mg); Powder for solution (200 mg/mL constituted)
Metokuriinijodidi Indication
For the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. CellCept should be used concomitantly with cyclosporine and corticosteroids.
Metokuriinijodidi Pharmacology
Mycophenolate mofetil is a prodrug of mycophenolic acid, an antibiotic substance derived from Penicillium stoloniferum. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase. Mycophenolic acid is important because of its selective effects on the immune system. It prevents the proliferation of T-cells, lymphocytes, and the formation of antibodies from B-cells. It also may inhibit recruitment of leukocytes to inflammatory sites.
Metokuriinijodidi Absorption
Rapidly absorbed following oral administration. In 12 healthy volunteers, the mean absolute bioavailability of oral mycophenolate mofetil relative to intravenous mycophenolate mofetil (based on MPA AUC) was 94%. Food (27 g fat, 650 calories) has no effect on the extent of absorption (MPA AUC) of mycophenolate mofetil.
Metokuriinijodidi side effects and Toxicity
Oral (LD50): Acute: 352 mg/kg [Rat], 1000 mg/kg [Mouse], and >6000 mg/kg [Rabbit]. Possible signs and symptoms of acute overdose could include the following: hematological abnormalities such as leukopenia and neutropenia, and gastrointestinal symptoms such as abdominal pain, diarrhea, nausea and vomiting, and dyspepsia.
Metokuriinijodidi Patient Information
No information avaliable
Metokuriinijodidi Organisms Affected
Humans and other mammals
